Julio Hajdenberg
Hematology & Oncology · Boston, MANPI 1255315958
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $439,845 of the $582,896 with a category attached, or 75.5%. It is spread thinly across 28 manufacturers, the largest accounting for just 20.9%. Reporting peaked in 2019 at $293,981 and has fallen 99.3% since, to $1,913 in 2025. Among hematology & oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 536 payments — averaging $1087.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$122K
- Incyte Corporation$85K
- Bristol Myers Squibb$80K
- EMD Serono, Inc.$62K
- Seagen Inc.$46K
- Astellas Pharma US Inc$31K
- plus $157K from 22 others
Across 134 payments — averaging $5353.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$238K
- Clovis Oncology, Inc.$185K
- E.r. Squibb & Sons, L.L.C.$100K
- Janssen Research & Development, LLC$86K
- Merck$79K
- Takeda Pharmaceuticals U.S.A., Inc.$20K
- plus $10K from 2 others
What the payments were for
- Consulting fees$74,32313%
- Speaking & faculty fees$439,84575%
- Travel & lodging$57,58110%
- Food & beverage$10,6512%
- Education$4970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 127 | $121,976 |
| Incyte Corporation | 70 | $85,422 |
| Bristol Myers Squibb | 58 | $80,414 |
| EMD Serono, Inc. | 64 | $62,070 |
| Seagen Inc. | 44 | $45,615 |
| Astellas Pharma US Inc | 22 | $30,840 |
| Novartis | 24 | $23,504 |
| Pharmacyclics LLC, An Abbvie Company | 17 | $23,081 |
| E.r. Squibb & Sons, L.L.C. | 18 | $17,678 |
| Verastem, Inc. | 18 | $16,521 |
| EUSA Pharma (US) LLC | 15 | $13,062 |
| AbbVie | 22 | $12,974 |
| Pfizer | 8 | $12,085 |
| Jazz Pharmaceuticals Inc. | 10 | $6,397 |
| Secura Bio, Inc. | 3 | $5,934 |
| Amgen | 3 | $5,841 |
| Bayer | 2 | $3,807 |
| Gilead | 1 | $2,700 |
| Clovis Oncology, Inc. | 1 | $2,055 |
| Exelixis Inc. | 1 | $1,980 |
| Astellas Pharma Global Development | 1 | $1,860 |
| GSK | 1 | $1,788 |
| Beigene USA, Inc. | 1 | $1,650 |
| Janssen Scientific Affairs, LLC | 1 | $1,560 |
| Myovant Sciences Inc. | 1 | $1,550 |
| AstraZeneca | 1 | $400 |
| Adaptive Biotechnologies Corporation | 1 | $78 |
| AVEO Pharmaceuticals, Inc. | 1 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$582,896 in reported general payments places this provider in the 95th percentile of 374 hematology & oncology providers in Massachusetts.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
- Daniel DeangeloBoston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.